BioCentury | Apr 23, 2007
Emerging Company Profile

Wittycell: Outwitting the immune response

...or NK cells and may be used in a therapeutic vaccine against cancer," Serra said. Truffle Venture...
BioCentury | Apr 23, 2007
Emerging Company Profile

Corporate Profile

...Institute Corporate partners: None Number of employees: 5 Funds raised: E1 million ($1.3 million) Investors: Truffle Venture...
BioCentury | Apr 7, 2006
Politics & Policy

France Biotech names Archinard chairman

...Philippe Archinard chairman. Archinard is CEO of Transgene (Euronext:Transgene). He replaces Philippe Pouletty, CEO of Truffle Venture...
BioCentury | Feb 28, 2006
Financial News

Cytomics raises EUR 10 million

...10 million ($11.9 million) in a series B round led by Edmond de Rothschild and Truffle Venture...
BioCentury | Feb 27, 2006
Tools & Techniques

Better ubiquitin screening

...SA, a CRO that specializes in Phase I trials. The series B round, which included Truffle Venture...
BioCentury | Jan 3, 2005
Finance

European VC leads

...France 2 Investment Partners Merlin Biosciences U.K. 2 Novo A/S Denmark 2 Quester U.K. 2 Truffle Venture...
BioCentury | Feb 16, 2004
Emerging Company Profile

Neovacs: Active immunity

Normally, the human immune system cannot recognize cytokines on its own because during early development it loses the ability to attack them. But sometimes it is desirable to temporarily harness the immune system to recognize...
BioCentury | Feb 16, 2004
Emerging Company Profile

Corporate Profile

Neovacs S.A. Paris, France Technology: Stimulating human polyclonal antibody response against cytokines and retroviral proteins Disease focus: AIDS, cancer, autoimmune disease, allergy Clinical status: Phase I/II Founded: Restarted 2003 by Truffle Ventures Corporate partners: Aventis...
BioCentury | Jun 16, 2003
Company News

Neovacs SA board of directors update

Neovacs SA , Paris, France Business: Antibodies, Infectious diseases Appointed: Philippe Pouletty, general partner of Truffle Ventures, as chairman; Jean-Jacques Bertrand, former chairman and CEO of Aventis Pasteur SA WIR Staff Infectious...
BioCentury | Jun 16, 2003
Finance

Ebb & Flow

The doomsday mood in European biotech is lifting. Since the market bottom in March, BioCentury's European and London indices now are tracking the upswing in U.S. biotech stocks. The BioCentury 100 Index, which consists primarily...
Items per page:
1 - 10 of 15
BioCentury | Apr 23, 2007
Emerging Company Profile

Wittycell: Outwitting the immune response

...or NK cells and may be used in a therapeutic vaccine against cancer," Serra said. Truffle Venture...
BioCentury | Apr 23, 2007
Emerging Company Profile

Corporate Profile

...Institute Corporate partners: None Number of employees: 5 Funds raised: E1 million ($1.3 million) Investors: Truffle Venture...
BioCentury | Apr 7, 2006
Politics & Policy

France Biotech names Archinard chairman

...Philippe Archinard chairman. Archinard is CEO of Transgene (Euronext:Transgene). He replaces Philippe Pouletty, CEO of Truffle Venture...
BioCentury | Feb 28, 2006
Financial News

Cytomics raises EUR 10 million

...10 million ($11.9 million) in a series B round led by Edmond de Rothschild and Truffle Venture...
BioCentury | Feb 27, 2006
Tools & Techniques

Better ubiquitin screening

...SA, a CRO that specializes in Phase I trials. The series B round, which included Truffle Venture...
BioCentury | Jan 3, 2005
Finance

European VC leads

...France 2 Investment Partners Merlin Biosciences U.K. 2 Novo A/S Denmark 2 Quester U.K. 2 Truffle Venture...
BioCentury | Feb 16, 2004
Emerging Company Profile

Neovacs: Active immunity

Normally, the human immune system cannot recognize cytokines on its own because during early development it loses the ability to attack them. But sometimes it is desirable to temporarily harness the immune system to recognize...
BioCentury | Feb 16, 2004
Emerging Company Profile

Corporate Profile

Neovacs S.A. Paris, France Technology: Stimulating human polyclonal antibody response against cytokines and retroviral proteins Disease focus: AIDS, cancer, autoimmune disease, allergy Clinical status: Phase I/II Founded: Restarted 2003 by Truffle Ventures Corporate partners: Aventis...
BioCentury | Jun 16, 2003
Company News

Neovacs SA board of directors update

Neovacs SA , Paris, France Business: Antibodies, Infectious diseases Appointed: Philippe Pouletty, general partner of Truffle Ventures, as chairman; Jean-Jacques Bertrand, former chairman and CEO of Aventis Pasteur SA WIR Staff Infectious...
BioCentury | Jun 16, 2003
Finance

Ebb & Flow

The doomsday mood in European biotech is lifting. Since the market bottom in March, BioCentury's European and London indices now are tracking the upswing in U.S. biotech stocks. The BioCentury 100 Index, which consists primarily...
Items per page:
1 - 10 of 15